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Abstract
The principal aim of this historical review- the first in a new series- is to present the basic concepts
that led to the discovery of NOV and to show how our ideas evolved regarding the role and
functions of this new class of proteins. It should prove particularly useful to the new comers and
to students who are engaged in this exciting field. It is also a good opportunity to acknowledge the
input of those who participated in the development of this scientific endeavour
Introduction
In this manuscript I am presenting milestones in our dis-
covery of NOV (CCN3), a founding member the CCN
family of regulatory proteins [1], now known to be com-
posed of six members that play critical roles in normal
fundamental biological processes including angiogenesis,
wound repair, regulation of cell spreading proliferation
and survival [2,3]. Alterations in the expression of CCN
genes are also associated with cancerogenesis [4,5].
The past
In my opinion, the « nov story » finds its roots in 1982
with the molecular cloning of a MAV-1(N) (myeloblasto-
sis associated virus type 1) proviral genome that was
shown to specifically induce nephroblastomas when
injected into day-old chickens [6,7]. As a fellow on leave
from the CNRS at UCLA in the laboratory of Pr. M. Bal-
uda, I had cloned both the v-myb oncogene [8] and c-myb
proto-oncogene [9] and I became interested in the molec-
ular basis for MAV-induced nephroblastomas, which
resemble the Wilms' tumors [10]. The MAV strains that
were used at this time were inducing nephroblastomas,
lymphoid leukosis and osteopetrosis [11]. Because these
strains were at best, plaque purified, it was not easy to
assess the biological properties of MAV.
Back at that time, the idea prevailed that retroviruses
induced tumors by inserting in the vicinity of cellular
proto-oncogenes. Pioneer work of Hayward, Astrin and
collaborators had opened the road for my interest in iden-
tifying the integration sites of MAV.
After my return to France, M. Brisac who was a student in
my laboratory was given the task to characterize the MAV
junction fragments in tumor DNA, with the help of Dr. G.
Dambrine at the INRA who provided animal facilities and
expertise in chicken pathology. Several tumors were
obtained and analyzed both at the histological level by
Dr. G. Plassiart and Pr. M. Wyers at the Ecole Vétérinaire
de Nantes, and at the molecular level in my laboratory.
Even though I had previously cloned a U3-specific probe
for MAV, these studies were seriously complicated by the
presence in the avian genome of endogenous sequences
that were cross-reacting with the structural MAV probes
that we used. Another student, J. Soret, who was working
on v-myb in my group took over this study when M. Brisac
left. He soon established that MAV nephroblastomas were
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polyclonal tumors and contained several rearranged pro-
viral genomes [7].
The very high efficiency of nephroblastomas induction by
MAV,100 % in 8 weeks, made it a unique model in which
to study the molecular basis of its tumorigenic potential
and to identify new potential oncogenes or tumor sup-
pressors.
The near past
At that time, V. Joliot, who came on as a graduate student
in my laboratory, was given a project aimed at identifying
the cellular and viral determinants for the restricted path-
ogenic potential of MAV-1(N). Part of her project
included the cloning of cellular DNA fragments contain-
ing MAV proviral sequences, so-called junction fragments,
in order to establish whether the expression of neighbour-
ing genes would be activated or repressed upon MAV inte-
gration.
The classical strategy at that time, consisted in preparing
genomic libraires of tumor DNA. A critical step in the pro-
cedure consisted in the preparation of good quality high
molecular weight DNA from tumor tissues samples which
are known to contain a significant amount of degraded
material if not collected and kept under proper conditions
[12]. A key point to our success in this approach was pro-
vided by the selection, as starting material, of three differ-
ent tumors showing different developmental stages. I
must say that the expertise of G. Dambrine, G. Plassiart
and M. Wyers was pivotal in making this choice.
When a senior scientist, Dr. C. Martinerie, who previously
worked on c-myb in my laboratory returned from a post
doctoral stay in USA, I offered her to join the MAV project
that V. Joliot had some difficulties to get moving. Eventu-
ally, the three libraires were prepared and their screening
permitted the cloning of MAV-containing tumor DNA
fragments. The next step in this strategy consisted in using
these DNA fragments as probes on Northern blots of RNA
species purified from avian normal and tumor samples.
Only one junction fragment detected sequences that were
differentially expressed in tumor and normal cells. In
tumor 725 this probe detected high levels of a 2.0 kb RNA
species that was not detected in normal adult kidney tis-
sues from 8 week-old chicken [13].
A cDNA library of chicken DNA was screened by V. Joliot
and C. Martinerie to isolate a cDNA species corresponding
to the sequences that were highly expressed in nephrob-
lastoma 725. When this cDNA was used as a probe, it was
found that the corresponding sequences were highly
expressed in all MAV-induced nephroblastomas [13].
Upon the suggestion of V. Joliot, the gene was designated
« nov » for « nephroblastoma overexpressed ». The nov
cDNA was encoded by a gene consisting of 5 exons which
showed a high similarity with two other genes – chicken
cef10 and the murine fisp12, subsequently  renamed
CCN1 and CCN2 (see below) – previously reported to be
immediate early genes whose expression was increased
upon transformation of fibroblasts by the src oncogene or
following serum stimulation of starved cells [14,15]. The
murine ortholog of CEF10 had been cloned as a gene
encoding a cystein-rich protein designated cyr61 [16] and
the human ortholog of Fisp12 had been cloned as an
immediate-early gene encoding a protein that was iso-
lated from Huvec (human umbilical vein endothelial
cells), on the basis of its cross reactivity with anti PDGF
antibodies [17].
Since nov was disrupted by MAV in only one nephroblas-
toma, we hypothesized that the integration of proviral
LTR sequences in the vicinity of nov might account for its
overexpression in the other avian tumors. However,
recent studies [18] have challenged this view and ques-
tioned the significance of nov overexpression in chicken
nephroblastomas (see below).
Isabelle Joubert who joined my team to prepare a PhD,
studied several other nephroblastomas induced by MAV
1(N) or by a strain of MAV2(O) that had been cloned by
V. Joliot [19] and reached the conclusion that all tumors
expressed high levels of nov. The coding frame of the full
length nov mRNA species was not altered in the tumors
that I. Joubert studied, therefore suggesting that high lev-
els of a normal nov protein are expressed in nephroblast-
omas [10].
In the second part of her thesis project, I. Joubert
attempted to establish whether MAV sequences were inte-
grated in the vicinity of nov in tumors expressing high lev-
els of full length nov mRNAs. Since our previous studies
permitted analysis of only 20 kb of sequences surround-
ing MAV LTRs in tumor DNA, we decided to construct
BAC (bacterial artificial chromosomes) libraries of tumor
DNA. Unfortunately, this approach was unsuccessful and
the question was left open until C.L. Li, an Assistant Pro-
fessor from China, joined our laboratory (see below).
Since MAV-induced nephroblastomas constituted a
unique model of the Wilms' tumor, a pediatric kidney
tumor arising in 1:6000 birth [20], we became interested
in establishing whether the expression of the nov gene
was also elevated in these tumors.
As a first step along this line, I had established a collabo-
ration with Pr. L. Strong and Dr. V. Huff (MD Anderson,
Houston) who both showed a lot of interest in checking
the status of nov in Wilms tumors. Screening of a HeLa
cell cDNA library provided by Pr. P. Chambon had per-Cell Communication and Signaling 2006, 4:3 http://www.biosignaling.com/content/4/1/3
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mitted C. Martinerie to clone the human nov ortholog
which was used by V. Huff to probe a Northern blot of
RNA species isolated from several diferent Wilm's tumors.
The results obtained indicated that increased expression
of nov was observed mainly in tumors showing a marked
stromal aspect [21]. Most interestingly, the increased
expression of nov was not always associated with Wilms
tumor development but appeared to be dependent upon
the origin and type of the tumors. The results obtained
also suggested the existence of an inverse relationship
between the expression of WT1 and nov [21].
This work led us to determine whether the transcription
factor WT1 might regulate negatively the transcription of
nov. With the help of G. Chevalier, a new PhD student in
my laboratory, C. Martinerie who was given this project,
cloned the nov promoter region and constructed several
reporter plasmids. The results obtained indicated that
WT1 downregulated indirectly the expression of nov [22].
The promoter region responsible for this effect did not
contain consensus WT1 binding sites but contained sev-
eral other sites for regulatory proteins that may potentially
interact with WT1 and be responsible for the negative reg-
ulation of the nov promoter activity.
Because cyr61 and ctgf had been shown to be immediate
early genes C. Martinerie and S. Middendorp, a master's
student in our group, analysed the expression of nov upon
stimulation of starved cells. Unfortunately, their results
did not permit us to establish whether nov was an imme-
diate early gene or not.
It is during these years that Dr. G. Scholtz in the laboratory
of Pr. H. Hanafusa informed me that nov was among the
genes whose expression was downregulated upon chicken
embryo fibroblast transformation by the v-src oncogene.
We met in New York to draw the lines of a collaboration
that eventually led G. Scholtz to establish that the expres-
sion of nov was associated with cell quiescence and was
downregulated upon serum stimulation of starved cells
[23].
To me these results were extremely stimulating because
they had important biological consequences: i) the asso-
ciation of nov expression with cell quiescence of CEF was
in total agreement with the negative effects of nov on CEF
proliferation that we had previously reported [13], ii) the
nov gene was not an immediate early gene. The three pro-
teins that had been proposed to constitute a new family of
multimodular proteins (CCN) were showing distinct bio-
logical properties.
At this time, Dr. W. Zumkeller, a post doc in Pr. P.
Schofield's laboratory, contacted me to undertake studies
regarding the possible functional relationship between
nov and IGFBPs. W. Zumkeller showed so much enthusi-
asm that I eventually got in touch with P. Schofield and
offered to come to Cambridge and discuss this topic with
both of them. The expertise of P. Schofield's in IGF biol-
ogy and WAGR syndrome provided the basis for studying
nov expression in Wilms tumors. G. Chevalier, was sent to
P. Schofield laboratory in Cambridge to initiate the study
of nov expression in Wilms tumors by in situ hybridiza-
tion. The preliminary results that were obtained identified
for the first time the blastemal cells as positive for nov
expression in Wilms Tumors. These conclusions were not
in full agreement with those reached previously with the
Houston group.
Ten years after MAV cloning: A new perspective
Dr. H. Yeger from the Hospital for Sick Children, Toronto
who I met at the 1995 AACR meeting in Toronto, pro-
posed to join our collaborative project and to perform
immunohisto chemistry (IHC) on normal developing
human embryo and on a wider panel of Wilms tumors.
Because the Wilms tumors belong to a very heterogenous
group of tumors, he suspected that the variability of the
samples that were used in our different studies might
account for the conflicted observations.
The proposed collaborative study was aimed to identify
the nature of cells positive for nov and to establish
whether the elevated expression of nov in tumors resulted
from increased expression in tumor cells or from the
clonal expansion of nov-expressing cells in the tumor. H.
Yeger used the antibodies that we had raised against the C-
terminal part of nov and the internal region of ctgf to
establish the expression profile of these two proteins dur-
ing human embryogenesis. Samples provided by P.
Schofield permitted to identify the sites of nov and ctgf
expression in normal first trimester human embryos
whereas Wilms tumor samples from the Hospital for Sick
Children were used to study nov expression in Wilms'
tumors. G. Chevalier, was offered to join this project and
was hosted by H. Yeger to complete this work and to con-
firm by IHC the preliminary in situ results that she had
obtained with Dr. F. Dieterlin and Dr. L. Pardaneau in
Nogent sur Marne. The work performed in collaboration
with the group at Nogent had permitted identification of
sites of nov expression in the chicken embryo from early
stages to birth. The results that were obtained had identi-
fied the developing cartilage and the nervous system as
major sites of nov expression in the chicken embryo
whereas the urogenital system, muscle and vessel
endothelium stained with less intensity.
The availabilty of a wide panel of tumor samples at The
hospital for Sick Children permitted us to perform a com-
prehensive study of nov expression in Wilms tumors that
shed new light on the role of nov in kidney tumorigenesisCell Communication and Signaling 2006, 4:3 http://www.biosignaling.com/content/4/1/3
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[24]. This study also established for the first time that the
levels of nov RNA and protein were not always matching.
Indeed, in spite of the low levels of nov RNA that were
detected in kidney podocytes, high and increasing
amounts of the nov protein accumulated in these cells
during development. These results provided the first clue
in favor of post transcriptional regulation of nov expres-
sion in normal tissues.
Based on the studies performed with the Wilms' tumors
and with a series of rhabdomyosarcoma tumors and cell
lines, H. Yeger had foreseen the implication that nov
could be involved in the development of muscle. Confo-
cal microscopy had shown co-localization of nov and
desmin in a rhabdomyosarcoma cell line (RD) induced to
undergo myotube differentiation in the presence of low
serum [Chevalier, Yeger, Perbal; unpublished observa-
tions]. Interestingly, nov was associated with a high
molecular weight complex in SDS-PAGE suggesting a very
stable protein interaction. Induction of differentiation
also produced an increase in the measurable level of nov.
Based on these observations, H. Yeger, back in 1998, send
us a detailed proposal in which he proposed a collabora-
tive study aimed to better understand the role of nov in
muscle differentiation. The completion of this project in
my group was unfortunately hampered by later events
(see below). It is now being pursued by previous members
of my group who have left the laboratory.
Soon after his return to Germany, W. Zumkeller who had
perceived the importance of this new developing fled,
introduced me to one of his colleague, Pr. M. Westphal, at
the Eppendorf clinic in Hamburg where I was presenting
our recent results.
M. Westphal who had established several cell lines from
human glioblastomas and astroctytomas showed a real
interest in the expression profile of nov in the nervous
sytem and he agreed to start a collaborative project whose
first aim was to determine whether the levels of nov
expression would be affected in his tumor cell lines, and
whether nov might be a good marker for typing or prog-
nosis of brain tumors. This project was given to Pr. Li Wen
Xin who at that time, was staying as an invited Professor
in my laboratory. The glioma cells showed a variable level
of nov expression, with the lowest levels of nov being
detected in the most agressive tumors. These results sug-
gested for the first time, an inverse correlation between
tumorigenicity and the expression of a ccn gene [25], an
observation in agreement with the antiproliferative activty
of nov on chicken embryo fibroblasts [13].
During one of my trips to China Pr. Li Wen Xin, organized
a meeting in Chonqing with Pr. W. Cai who was interested
in the nervous system development and was looking for
genes differentially expressed in normal and pathological
conditions. We both decided to undertake with Dr. Su an
in situ analysis of ccn3 gene expression in the nervous sys-
tem of human developing embryo. This study confirmed
that nov expression was associated with the development
of the nervous system in normal human embryos and per-
mitted identification of the positive neurons in medulla
horns the cerebral cortex and ganglia as major sites of nov
expression [26]. At the same time, preliminary results
were obtained suggesting that nov expression might be
associated with the establishment of cognitive functions
in normal rats [27]. The staining of nov in human nervous
system was matching the results that we had previously
obtained with the chicken model.
The unique human material provided by P. Schofield's
collaborators permited H. Yeger to establish a compre-
hensive pattern for the nov and ctgf protein in human
developing tissues and led to a thorough description of
nov protein expression in normal human developing
embryo [28].
The overlaping results that were obtained in chicken
mouse and human and confirmed that nov expression
was not restricted to the kidney and strongly suggested
that nov was playing a role in differentiation.
For the sake of homogeneity that is required for a PhD
defense, I suggested G. Chevalier to concentrate on the
expression of ccn3 during the normal development of
chicken kidney and in MAV-induced nephroblastomas.
These studies were performed in close collaboration with
C. Khelifi and V. Joliot who were in charge of identifying
the viral and cellular determinants responsible for the
high specificity of MAV tumorigenic potential. Studies
performed by G. Chevalier and Pr. Y. Cherel in Nantes
established that the blastemal cells which undergo epithe-
lial differentiation are the target for MAV infection in the
avian kidney (manuscript in preparation). The blastemal
cells which were positive for ccn3 also express high levels
of viral sequences and give rise to the tumor cells that
develop later. Hence the concept emerged of MAV induc-
ing the polyclonal proliferation of tumor cells that already
express nov instead of increased nov expression being
driven by enhancer sequences of the MAV LTR. To tackle
this problem, and better understand the relationship that
might exist between nov expression and the induction of
nephroblastomas by MAV, we have undertaken an identi-
fication of MAV integration sites in the chicken genome at
a larger scale. Because a series of pulse field electrophore-
sis performed by I. Joubert indicated that a limited
number of MAV integration sites were represented in
viral-induced nephroblastomas [10] we planned a strat-
egy based on the use of bacterial artificial chromosomes
(BACs) Unfortunately the initial attemps of I. Joubert toCell Communication and Signaling 2006, 4:3 http://www.biosignaling.com/content/4/1/3
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construct BAC libraries from tumor and normal genomic
kidney DNAs failed. After discussing the question with Dr.
R. Zoorob and Dr. C. Auffray at Villejuif, we agreed upon
a collaborative approach based on the use of a BAC library
of chicken DNA that had been constructed by R. Zoorob.
As a first step in this approach, V. Joliot isolated a series of
cellular DNA fragments which were contiguous to the
MAV insertion sites previously identified in nephroblast-
omas.
While the work performed by G. Chevalier did not allow
for unambiguous identification of the sites of nov expres-
sion in early stages of kidney development and in devel-
oping nephroblastomas, the studies performed by C.
Khelifi eventually identified viral components involved in
nephroblastoma development [29].
The screening of the BAC library that was pursued by C. L.
li soon indicated that nov was not a common integration
site for MAV in viral-induced nephroblastomas, a conclu-
sion that was strengthened through physical mapping of
MAV integration sites by fluorescent in situ hybridization
(FISH) analysis [18]. Quite interestingly, a study per-
formed on MAV2-induced tumors reached similar conclu-
sions [30]. However, in most of the MAV2-induced
tumors, the level of nov expression was not increased as
compared to normal kidney. This recent result opened
new questions regarding the biological significance of nov
overexpression in avian tumors, and reinforced the con-
clusion drawn from the analysis of Wilms' tumors, that
the nov acronym was not appropriate. Hence the need for
a new nomenclature (see below).
Because the results obtained by G. Chevalier during her
stay at Nogent sur Marne had pointed to cartilage and
nervous system as major sites for ccn3 expression early
during chicken development, I recruited Dr. M. Laurent, a
senior scientist who was seeking a laboratory in which to
work, and I offered her to study the role of ccn3 in the
development of cartilage and nervous system differentia-
tion, both in normal and pathological conditions. At the
same time I hired a master's student, W. Barbot, to work
with M. Laurent under my scientific supervision.
The role of nov in cartilage differentiation had been
clearly documented by both G. Chevalier and W. Barbot.
Their observations set the stage for further studies regard-
ing the involvement of nov in the control of limbs growth,
in concert with other members of the CCN family that
had already been involved in chondrogenesis. Unfortu-
nately, later events [31] interfered with the publication of
these results which were included in a general review [3].
For many years, the multimodular organization of the
CCN proteins and the oncogenic activation of nov result-
ing from its amino truncation had raised in my mind a
considerable interest regarding the relationships existing
between the structure and the functions of the CCN pro-
teins.
To get a better insight into the biological properties of nov
and the potential role of each individual module, two dif-
ferent approaches were undertaken. On one hand I had
asked C. Martinerie to work out conditions for the purifi-
cation of nov, and on the other hand, I used the two
hybrid strategy to identify the proteins that physically
interact with nov.
The procedure for purification of the CCN3 protein using
Cibacron blue and reverse phase chromatography that
was developed with Y. Bluquit at the Curie Institute,
yielded low levels of protein in spite of using supernatants
from SF9 insect cell cultures infected with a recombinant
baculovirus driving the expression of CCN3. Switching to
a 6-HIS tagged CCN3 protein appeared of potential inter-
est to increase the purification yield. The construction of
such recombinant clones was initiated later with C. Mar-
tinerie and E. Dulorme, an undergraduate student who
spent some time to get trained in our team [32]
Because the insertion of MAV confered oncogenic proper-
ties on the amino truncated nov protein, we reasoned that
the lack of the IGFBP-like domain present at the amino
terminus of the CCN proteins might be responsible for
the upregulation of cell growth. To check this hypothesis,
we contacted Dr. M. Binoux and asked him to check
whether CCN3 would bind IGF. The results obtained by
ligand blotting were negative therefore suggesting that
CCN proteins were not IGF binding proteins and were not
involved in IGF signaling.
About a year later, the group of Dr. R. Rosenfeld re-discov-
ered that CCN proteins were sharing partial identity with
IGFBPs. Even though this relationship had been clearly
mentioned and previously discussed in our publications
and those from Pr. G. Grotendorst and Pr. L. Lau, an
IGFBPr nomenclature was proposed for the CCN proteins.
Following R. Rosenfeld's manuscript M. Binoux became
interested in CCN proteins and introduced me to Pr. Y. Le
Bouc who was supposed to take over his directionship.
After I had presented our projects, Y. LeBouc who did not
know much about the CCN proteins, realized the poten-
tial interest of the structural realtionship between IGFBPs
and CCNs. We both agreed in 1998 that I would be a co-
applicant on the renewal of the Inserm unit that was
needed after M. Binoux retirement. Our two laboratories
were showing complementary expertise; Le Bouc's was
providing the IGF biology knowledge and access to
patient samples, my group was bringing a solid molecular
biology and the nov system. Furthermore, we had estab-Cell Communication and Signaling 2006, 4:3 http://www.biosignaling.com/content/4/1/3
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lished with H. Yeger by immunofluorescence and western
blotting of samples provided by P. Schofield that nov was
highly expressed in adrenal. Le Bouc's group could pro-
vide human adrenal tumor samples that were needed to
explore the potential deregulation of nov in these tumors.
A new collaboration was born.
At that time, two colleagues, Pr. S. Kyurkchiev from Sofia
and Pr. G. Thomopoulos from Thessaloniki joined my
laboratory for a short time as invited Professors of the
Paris 7 University.
Because the analysis of the nov protein in tumor samples
required purified antibodies, I asked Pr Kyurkchiev who is
a talented immunobiologist to join the adrenocortical
tumor project. During his stay, Pr. Kyurkchiev purified the
antibodies that were extensively used by C. Martinerie and
M. Laurent to perform their analysis of the nov protein in
normal and tumor tissues [31].
In the meantime, thanks to B. Roizman, I had spent a cou-
ple of month in his laboratory at the University of Chi-
cago in 1997, to screen cDNA libraries of normal and
tumor tissues to identify potential partners of nov. The
continuous help and advice that I got from B. Roizman
was extremely useful and permitted me to isolate several
candidates, the partial sequencing of which identified
integrins, calcium binding proteins, fibulin and a subunit
of RNA polymerase II as interacting with nov. During this
period, I decided to re-examine an observation that had
puzzled me. Back in 1997, after I was invited to give a talk
by Pr. Roy Burman at the USC Medical Center in Los
Angeles, one of his colleagues who had evaluated our nov
antibody claimed that it was not specific because it was
staining the nucleus of HeLa cells. Even though this result
was not in agreement with our conventional way of think-
ing about a secreted regulatory protein, I performed a
series of immunostainings with two different sources of
nov-antibody which indeed confirmed that the nucleus of
two cancer cell lines (HeLa and 143 osteosarcoma cells)
stained positive for nov. These observations eventually
helped us to establish that a truncated nov protein was
located in the the nucleus of these tumor cells whereas it
was not detected in the VERO normal monkey kidney
cells. Pr. B. Roizman suggested me to run confocal analy-
sis on HSV infected cells with antibodies raised against
ICP4 and ICP8, two viral proteins involved in transcrip-
tion and replication, respectively. The colocalization of
nov and ICP4 in HSV-infected cells strongly suggested that
the nuclear nov variant might act as a transcriptional reg-
ulator.
The large number and the the great variety of potential
nov partners were totally unexpected. Thanks to Dr. A.
Sentenac, I could spend a few weeks in the Service de Bio-
chimie et Genetique Moleculaire, at Saclay, where I could
confirm the interaction of CCN3 with rpb7 of
RNApolymeraseII, reisolate candidate clones and estab-
lish that the constitutive modules of nov were differen-
tially implicated in these interactions. Most interestingly,
the CT module was showing a high capacity to interact
with some of the candidate partners. In 1999, I hired R.
Sainson, a master degree student, to help me in this
project. In a couple of month, thanks to D. Nolibe at the
INSTN, we could confirm the interactions of nov with
fibulin 1C and several other candidates.
After the move of my team to the Inserm, we could final-
ize this work with the help of C. Martinerie and establish
that the C-terminal domain of nov was sufficient to per-
mit its physical interaction with fibulin 1C [33]. These
results confirmed our previous observations that the full
length nov protein was localized in the extracellular
matrix and provided the first clue for nov acting in coop-
eration with proteins involved in cell attachement and
intercellular signaling. In this work we could also estab-
lish that an aminotruncated nov protein lacking the two
first modules of CCN proteins was produced in the condi-
tioned medium of insect cells transfected by a nov recom-
binant baculovirus. Inasmuch as the amino terminus of
the truncated nov protein was identical to the aminoter-
minus of a previously described variant ctgf [34] we con-
cluded that cleavage was resulting from a proteolytic
cleavage involving a specific protease yet to be identified.
The two major perspectives open by this work came from
the fact that i) the truncated nov protein was binding fibu-
lin 1C with a much higher affinity than the full length nov
protein, therefore suggesting that the ratio of truncated
over full length forms might be critical in regulating the
biological activities of nov, ii) the truncated form that was
detected in the conditioned medium was structurally
identical to the nuclear nov variant. Since no evidence for
alternative splicing has been obtained as yet, this observa-
tion suggested that the truncated nov variant might be
internalized by a mechanism yet to be identified [3].
With the help of Pr. G. Thomopoulos, a distinguished
electron microscopist, we could confirm by the immuno-
gold labeling that the nov protein could be detected both
in the cytoplasm and in the nuclear pores of adrenocorti-
cal cells [35]. Furthermore, the nov protein detected in the
cytoplasm was not embeded in vesicles, therefore rein-
forcing the potential existence of un conventional process
responsible for internalization of the truncated protein
generated by proteolytic digestion at the cell membrane
[3].Cell Communication and Signaling 2006, 4:3 http://www.biosignaling.com/content/4/1/3
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The beginning of a new era : the antiproliferative activity 
of CCN3 uncovered
It is during a trip in Toronto, on the way to meet Dr. H.
Yeger, that I thought there was a strong need for an Inter-
national Meeting about CCN genes and proteins. After
discussing the matter with H. Yeger, who was very enthu-
siatic, I contacted G. Grotendorst and L. Lau. Both of them
showed a great interest in this project. Back in France, I
organized the First International Workshop on the CCN
family of genes that was to be held from October 17–19,
2000 in Saint Malo. This bi-annual meeting became a
must have event because it was fulfilling the needs of
many colleagues in the field to discuss and present their
new results in a friendly atmosphere.
During the preparation of this meeting, G. Grotendorst, L.
Lau and myself agreed to write a scientifically based rebut-
tal to the proposal of Rosenfeld to rename CCN proteins
[36,37]. Recent results have now confirmed that indeed,
the IGFBP domain of nov does not function as an IGF
binding domain in the context of IGFBP3 [38].
The proposal for a unique CCN nomenclature was dis-
cussed and approved at the first workshop [39]. The CCN
nomenclature found its justification in the variety of
names attributed to the same CCN proteins, and the con-
fusion that resulted from names which were often mis-
leading, restrictive, or inappropriate [40]. The
International CCN society [41] was created to consolidate
and favor relationship and scientific exchange between
worldwide members. In my opinion, these two events
were pivotal for the recognition of the CCN field as a
whole.
CCN3 was born.
B. Cadot, a new master student in my laboratory got
involved in two collaborative studies in which we exam-
ined the potential usefulness of CCN3 detection in
human prostate tumors and renal cell carcinoma (RCC)
for prognosis, typing and therapy.
The results that were obtained in collaboration with Dr. R.
Tatoud at Norwich established that a higher expression of
CCN3 was associated with more advanced stages of pros-
tate tumors, and suggested that in this system, increased
proliferation that occurs upon transformation of prostate
cells correlates with CCN3 expression [42]. Similarly, the
analysis of CCN3 expression that was performed with Dr.
AF Gogel, in a series of cell lines representing increasing
grades of RCC, led to the conclusion that in these cells an
elevated expression of CCN3 was associated with higher
grades and better ability to develop tumors in SCID mice
[43].
While I was hosted by Pr. B. Roizman and Pr. R. Weichsel-
baum for another short stay at the University of Chicago,
we examined in greater detail preliminary conflicting data
that had been obtained by M. Laurent in my own labora-
tory and by H. Wang in R. Weichselbaum's. A few stable
transfectants had been isolated from the G59 glioma cell
line by M. Laurent when she was working in my group.
While M. Laurent claimed that the expression of ccn3 did
not have any obvious phenotypic effects, Dr. Wang
observed that expression of ccn3 in these same cells
altered their proliferation and tumorigenic potential.
Experiments were repeated during my stay and the results
that were obtained clearly established that the expression
of ccn3 reduced significantly both cell proliferation and
tumorigenicity [44].
To me, these results were of prime importance because i)
they confirmed the previous observations of Dr. Li which
established an inverse relationship between tumor agres-
siveness and expression of ccn3 [25], and ii) they sug-
gested that the biological effects of ccn3 might be
dependent upon the cellular context since in prostate car-
cinoma and RCC cells the relationship was direct.
At that time, Dr. A. Lombet and V. Martinez, a PhD stu-
dent in my laboratory got the first evidence that the addi-
tion of recombinant CCN3 protein to SKNSH cells in
culture resulted in a marked increase of intracellular con-
centration of calcium ions. Since C.L. Li had confirmed
that CCN3 was interacting with the calcium binding pro-
tein S100A4, the effects of CCN3 on calcium concentra-
tion had a lot of potential meanings [45,46]. Upon the
suggestion of A. Lombet, we then investigated whether
CCN3 had an effect on ion channeling by performing
patch clamp with the help of Pr. D. Tritsch and P. Vincent
in Paris. Not only did the results that we obtained confirm
that the increased calcium uptake was accompanied by a
burst of voltage-dependent K+ (BK) current, but they also
established that CCN3 was blocking sodium channels
very efficiently [47].
Since the addition of CCN3 triggered calcium uptake by a
non-voltage dependent channel and/or ER calcium mobi-
lisation in a cell specific way [45] it would be interesting
to check whether the different effects that were observed
with the various cell types that we used were in any way
related to the quite different levels of endogenous ccn3
expressed by these cells.
In nany case, these results conferred for the first time a
biological activity on CCN3 and established CCN3 as a
genuine signaling protein.
Because the elevated expression of CCN3 in transformed
cells appeared to vary with the origin of the tumors, it wasCell Communication and Signaling 2006, 4:3 http://www.biosignaling.com/content/4/1/3
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quite interesting to establish the pattern of CCN3 expres-
sion in a much wider range of tumors. For this purpose, I
engaged my laboratory in a series of collaborations that
proved extremely fruitful.
Twenty years after MAV cloning: the picture is getting in 
focus
From the immunocytochemistry analysis and RNA profil-
ing that was performed on various tumor types we could
draw the following conclusions. An elevated expression of
CCN3 was associated with tumor differentiation and
good prognosis in the case of Wilm's tumors, chondrosa-
rcomas, osteosarcomas, neuroblastomas and chronic
myeloid leukemia, whereas it was associated with an
increased proliferation rate and/or metastases in the case
of RCC, prostate carcinomas, and Ewings tumors
[24,39,43,48-50].
The study performed with B. Alman's group also estab-
lished for the first time that the expression of CCN3 was
indeed required for cartilage differentiation [49].
It was also shown in two other collaborative studies using
either constitutive or inducible expression vectors, that
the ectopic production of ccn3 induced a dramatic reduc-
tion of cell proliferation in all the tumor cells tested
[51,52]. Therefore, the antiproliferative activity of CCN3
was not restricted to glioma cells but could be considered
as a genuine common feature. Along this line, it will be
interesting to determine whether the effects of CCN3 on
intracellular calcium concentration are responsible for its
growth inhibitory effects.
The case of Ewing tumors was of particular interest
because in this sytem CCN3 was acting as a double edge
sword. On one hand, the expression of ccn3 reduced cell
proliferation, but on the other hand, the expression of
ccn3 in primary tumors was associated with an increased
risk of developing metastases [48,52].
The identification of new partners for CCN3 provided
important clues regarding its mode of action.
Among the many potential partners for ccn3 that I had
isolated in the two hybrid screen performed in B. Roiz-
man's laboratory, were integrins, notch, a ligand of Zo1
protein, and a few nuclear proteins.
It is during a trip in Tokyo, where I was invited to give a
talk by Pr. J. Ikawa, that I met Dr. K. Katsube who
expressed a strong interest for the ccn3 gene expression
pattern and its possible relationship with the Notch recep-
tor. A very fruitful collaboration was set up and a few years
later, Notch1 was shown to physically interact with CCN3
[53-55].
During the same period of time, I was contacted by A. Gel-
haus in Essen, who discovered that choriocarcinoma cells
induced to express connexin43 were upregulating the
expression of ccn3. From the collaboration that I had ini-
tiated with C. Naus along the study of gliomas [44] I real-
ized that there might be a tight link between the
expression of ccn3 and connexins and I suggested A. Gel-
haus to check whether the forced expression of ccn3
would have any effect on connexin 43. At the same time,
C. Naus suggested that connexin 43 and CCN3 might
interact. In two simultaneous publications, we reported
that the physical interaction of CCN3 with connexin and
inter-connected expression of these two genes, might pro-
vide important clues for understanding the role of con-
nexins in cancer. Indeed, cells lacking Cx43 expressed very
low levels of CCN3, grew faster and were more tumori-
genic than the cells which were positive for Cx43 and
expressed CCN3 [51,56].
From these studies, it appeared that CCN3 was physically
interacting with many different proteins, as suggested by
the initial results of the two hybrid screening. The differ-
ent nature and subcellular localisation of these partners
was probably the reason why CCN3, as other CCN pro-
teins, was involved in such a variety of biological func-
tions [57]. Because CCN3 was obviously involved at
different levels of cell signalling, I proposed that CCN3
might be engaged in multimolecular complexes, where it
could play a scaffolding-type of function, allowing the
coordination of different signaling pathways [3,58]. In
this model, the functions and sites of actions of CCN3 are
determined by combinatorial events that depend upon
the bioavailability of the various components involved in
constitution of the complexes. Multifunctional complexes
have already been reported to play critical roles in the
biology of eucaryotic cells.
Another fundamental aspect of the CCN3 biology
emerged from our recent studies.
From the early report of CCN3 detection in nuclear
extracts and interaction of CCN3 with RNA polymerase II
subunit 7 [59], we have explored the possible functions of
aminotruncated CCN3 variants in the regulation of tran-
scription.
Work performed by N. Planque, an Associate Professor in
my laboratory, recently established that any alteration of
the aminoterminus of the CCN3 protein that would result
in the loss of the signal peptide would also result in the
nuclear addressing of the variant CCN3 [60]. This situa-
tion is not unique to CCN3 since a number of proteins
that are involved in outside signaling have been detected
in the nucleus of eucaryotic cells. Although the biological
significance of this dual localisation is not always clear, itCell Communication and Signaling 2006, 4:3 http://www.biosignaling.com/content/4/1/3
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is opening up very interesting perspectives in cell biology.
In the case of CCN3, N. Planque established that the CT
domain contains a nuclear localisation signal that can
drive the aminotruncated CCN3 proteins to the nucleus.
Furthermore, the CT domain of CCN3 confers on the pro-
tein the capacity to inhibit transcription [60].
These results are of considerable importance in the light of
the transforming activity of the truncated CCN3 protein
that was expressed in MAV-induced nephroblastoma [13].
Truncation of the CCN3 protein might occur under chro-
mosomal rearrangements and mutagenic events that
occur during tumor progression. Alternatively, the well-
documented increased production of proteases by tumor
cells might also lead to large quantities of the truncated
CCN3 variant that are detected in the conditioned
medium of CCN3-expressing cells [61] and consecutive
increased internalization of these variants. Along this line,
we have proposed that a balanced production of full
length growth-inhibitory CCN3 protein and of truncated
growth-stimulatory CCN3 truncated variant is required
for appropriate cell proliferation and differentiation. Any
event disrupting this balance would result into abnormal
signaling that might participate in the establishment or
maintenance of the tumor state. Whether this situation
also applies to other CCN proteins is a challenging ques-
tion.
The near future ..
At a first glance it may seem that the variety of functions,
interactions, and sites of expression that have been
assigned to CCN3 make it extremely difficult to categorize
it. The pleiotropic functions of CCN3 likely reflect its abil-
ity to interact with several key regulatory proteins and lig-
ands and its central place in the control of cell signaling.
As yet the antiproliferative activity of CCN3 is the only
function that is common to all situations in which the
biological activity of CCN3 has been assessed. The recent
demonstration that the antiproliferative activity of CCN3
constitutes a critical factor in the control of 3D spatial
localisation of melanocytes [62], provides the first exam-
ple of a biological situation in which this inhibitory effect
is required for the maintenance of a normal phenotype in
human skin. Work which is in progress with other normal
tissues, is expected to provide more examples that will
confirm the central role of CCN3 in the control of normal
cell behavior.
Studies performed on tumor cells have allowed to pin-
point several aspects of CCN3 biology that are altered
upon initiation or during progression of cancers. Future
challenges will include the use our partial knowledge in
the development of new tools for molecular diagnosis
and therapy.
Preliminary results that have been obtained in various
pathological situations aside from cancer, have also
pointed CCN3 as a key regulator of potential interest in
molecular medicine [47]. The production of a recom-
binant protein of reliable quality should permit us to pro-
ceed along the way of targeted therapy. This aspect will
require energy, talent and inventiveness.
The discovery of CCN3 as an antiproliferative protein
involved in the control of normal growth offers enormous
potential interest for translational research. I strongly
believe that in the near future, the CCN family of proteins
will get much more attention. In my opinion, the assign-
ment of a universal essential function such as the growth
inhibitory effect of CCN3, might help considerably to
attract new scientists in this relatively new field.
Conclusion
In this historical review, I have presented a personal
accounting of what I consider as a very exciting and chal-
lenging scientific journey. It is not meant to be a totally
encompassing scientific accounting of the CCN3 field, as
we all do appreciate the significant participation of others.
Although the focus of this review was on CCN3, it is quite
obvious to me that it is necessary to consider its biological
properties in the context of the whole family of CCN pro-
teins [63]. One can easily predict that physical and func-
tional interactions between the different members of the
CCN family of proteins should permit fine tuning of their
individual functions both in normal and pathological
conditions.
It may seem a long road to go but I am quite confident
that the growing interest in CCN proteins will fuel our
progress at an, as yet, unexpected pace and efficiency.
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